Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 1704 | 2447 | 37.6 | 81% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 21 | 35063 | OSTEOPOROSIS//OSTEOPOROSIS INTERNATIONAL//BONE MINERAL DENSITY |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | ALENDRONATE | Author keyword | 107 | 30% | 12% | 301 |
| 2 | RISEDRONATE | Author keyword | 87 | 43% | 6% | 157 |
| 3 | BISPHOSPHONATES | Author keyword | 83 | 16% | 19% | 466 |
| 4 | IBANDRONATE | Author keyword | 71 | 44% | 5% | 124 |
| 5 | POSTMENOPAUSAL OSTEOPOROSIS | Author keyword | 47 | 28% | 6% | 141 |
| 6 | ATYPICAL FRACTURE | Author keyword | 45 | 83% | 1% | 25 |
| 7 | ATYPICAL FEMORAL FRACTURE | Author keyword | 44 | 85% | 1% | 23 |
| 8 | BISPHOSPHONATE | Author keyword | 41 | 15% | 10% | 250 |
| 9 | DENOSUMAB | Author keyword | 27 | 24% | 4% | 100 |
| 10 | ATYPICAL FEMUR FRACTURES | Author keyword | 20 | 100% | 0% | 9 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | ALENDRONATE | 107 | 30% | 12% | 301 | Search ALENDRONATE | Search ALENDRONATE |
| 2 | RISEDRONATE | 87 | 43% | 6% | 157 | Search RISEDRONATE | Search RISEDRONATE |
| 3 | BISPHOSPHONATES | 83 | 16% | 19% | 466 | Search BISPHOSPHONATES | Search BISPHOSPHONATES |
| 4 | IBANDRONATE | 71 | 44% | 5% | 124 | Search IBANDRONATE | Search IBANDRONATE |
| 5 | POSTMENOPAUSAL OSTEOPOROSIS | 47 | 28% | 6% | 141 | Search POSTMENOPAUSAL+OSTEOPOROSIS | Search POSTMENOPAUSAL+OSTEOPOROSIS |
| 6 | ATYPICAL FRACTURE | 45 | 83% | 1% | 25 | Search ATYPICAL+FRACTURE | Search ATYPICAL+FRACTURE |
| 7 | ATYPICAL FEMORAL FRACTURE | 44 | 85% | 1% | 23 | Search ATYPICAL+FEMORAL+FRACTURE | Search ATYPICAL+FEMORAL+FRACTURE |
| 8 | BISPHOSPHONATE | 41 | 15% | 10% | 250 | Search BISPHOSPHONATE | Search BISPHOSPHONATE |
| 9 | DENOSUMAB | 27 | 24% | 4% | 100 | Search DENOSUMAB | Search DENOSUMAB |
| 10 | ATYPICAL FEMUR FRACTURES | 20 | 100% | 0% | 9 | Search ATYPICAL+FEMUR+FRACTURES | Search ATYPICAL+FEMUR+FRACTURES |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | NONVERTEBRAL FRACTURES | 195 | 54% | 10% | 250 |
| 2 | FRACTURE INTERVENTION TRIAL | 188 | 58% | 9% | 217 |
| 3 | POSTMENOPAUSAL OSTEOPOROSIS | 158 | 21% | 27% | 668 |
| 4 | ALENDRONATE THERAPY | 157 | 63% | 6% | 159 |
| 5 | ALENDRONATE | 154 | 23% | 25% | 601 |
| 6 | SUPPRESSED BONE TURNOVER | 146 | 72% | 5% | 114 |
| 7 | VERTEBRAL FRACTURES | 122 | 22% | 20% | 501 |
| 8 | RISEDRONATE | 121 | 36% | 11% | 269 |
| 9 | MONTHLY ORAL IBANDRONATE | 116 | 82% | 3% | 68 |
| 10 | ORAL ALENDRONATE | 90 | 53% | 5% | 121 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references |
% act. ref. to same field |
|---|---|---|---|---|
| Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research | 2014 | 105 | 85 | 78% |
| Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday | 2013 | 72 | 68 | 69% |
| Long-Term Use of Bisphosphonates in Osteoporosis | 2010 | 168 | 55 | 75% |
| Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review | 2014 | 16 | 45 | 78% |
| Denosumab for the treatment of osteoporosis | 2015 | 3 | 45 | 49% |
| Atypical fractures of the femur and bisphosphonate therapy A systematic review of case/case series studies | 2010 | 95 | 55 | 75% |
| A systematic review of persistence and compliance with bisphosphonates for osteoporosis | 2007 | 204 | 28 | 71% |
| Safety issues with bisphosphonate therapy for osteoporosis | 2014 | 11 | 96 | 67% |
| Ulnar fractures with bisphosphonate therapy: a systematic review of published case reports | 2015 | 1 | 29 | 72% |
| Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women | 2008 | 123 | 95 | 66% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | BONE HLTH OSTEOPOROSIS | 8 | 33% | 0.8% | 20 |
| 2 | KLINIKUM LEVERKUSEN | 7 | 30% | 0.8% | 19 |
| 3 | INTEGRATED SPORTS MED | 6 | 26% | 0.8% | 20 |
| 4 | REG DRUG EVALUAT INFORMAT CREVIF | 6 | 100% | 0.2% | 4 |
| 5 | UNITE EXPLORAT METAB OS CARTILAGE | 6 | 100% | 0.2% | 4 |
| 6 | UNIT 831 | 5 | 27% | 0.7% | 17 |
| 7 | RHEUMATOL OSTEOL GASTROENTEROL 2 | 4 | 75% | 0.1% | 3 |
| 8 | BONE CARTILAGE METAB UNIT | 4 | 19% | 0.7% | 18 |
| 9 | ODENSE PATIENT DATA EXPLORATORY NETWORK OPEN | 4 | 46% | 0.2% | 6 |
| 10 | PUBL HLTH EPIDEMIOL HLTH ECON | 4 | 17% | 0.8% | 20 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000187390 | BRONJ//OSTEONECROSIS OF THE JAW//ONJ |
| 2 | 0.0000179761 | FRAX//OSTEOPOROSIS INTERNATIONAL//WHO ABORATING METAB BONE DIS |
| 3 | 0.0000144566 | TERIPARATIDE//PTH//REG BONE |
| 4 | 0.0000114582 | ALENDRONATE SODIUM//1 NAPHTHYLISOTHIOCYANATE//OLPADRONATE |
| 5 | 0.0000100542 | STRONTIUM RANELATE//STRONTIUM CONTAINING HYDROXYAPATITE//CALCIUM POLYPHOSPHATE |
| 6 | 0.0000094184 | VERTEBRAL FRACTURE//VERTEBRAL FRACTURE ASSESSMENT//VERTEBRAL MORPHOMETRY |
| 7 | 0.0000085277 | RALOXIFENE//TISSUE SELECTIVE ESTROGEN COMPLEX//BAZEDOXIFENE |
| 8 | 0.0000081656 | ZOLEDRONIC ACID//SKELETAL RELATED EVENTS//BONE METASTASES |
| 9 | 0.0000067326 | TRABECULAR BONE SCORE//HIP AXIS LENGTH//HIP STRUCTURE ANALYSIS |
| 10 | 0.0000067181 | BONE TARGETING//OSTEOTROPIC DRUG DELIVERY SYSTEM//FARNESYL PYROPHOSPHATE SYNTHASE |